Current clinical regulation of PI3K/PTEN/Akt/mTOR signalling in treatment of human cancer
Published 2014 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Current clinical regulation of PI3K/PTEN/Akt/mTOR signalling in treatment of human cancer
Authors
Keywords
Cancers, PTEN expression, Targeted therapy, PI3K/mTOR inhibitors
Journal
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
Volume 141, Issue 4, Pages 671-689
Publisher
Springer Nature
Online
2014-08-22
DOI
10.1007/s00432-014-1803-3
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- 69P * SAFETY AND EFFICACY OF MK-8669 (RIDAFOROLIMUS) + MK-2206 (AKT INHIBITOR) IN PATIENTS WITH ADVANCED BREAST CANCER WITH PI3K PATHWAY DEPENDENCE
- (2014) S. Gupta et al. ANNALS OF ONCOLOGY
- Roles of PTEN (Phosphatase and Tensin Homolog) in Gastric Cancer Development and Progression
- (2014) Wen-Ting Xu et al. Asian Pacific Journal of Cancer Prevention
- MicroRNA-375 inhibits colorectal cancer growth by targeting PIK3CA
- (2014) Yihui Wang et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- miR-17 inhibitor suppressed osteosarcoma tumor growth and metastasis via increasing PTEN expression
- (2014) Yong Gao et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110 , for relapsed/refractory chronic lymphocytic leukemia
- (2014) J. R. Brown et al. BLOOD
- Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of SAR245409 (XL765), a Novel, Orally Administered PI3K/mTOR Inhibitor in Patients with Advanced Solid Tumors
- (2014) K. P. Papadopoulos et al. CLINICAL CANCER RESEARCH
- Phase Ib Study of Buparlisib plus Trastuzumab in Patients with HER2-Positive Advanced or Metastatic Breast Cancer That Has Progressed on Trastuzumab-Based Therapy
- (2014) C. Saura et al. CLINICAL CANCER RESEARCH
- The Search Continues
- (2014) Larissa A. Meyer et al. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
- Phase I study of PF-04691502, a small-molecule, oral, dual inhibitor of PI3K and mTOR, in patients with advanced cancer
- (2014) Carolyn D. Britten et al. INVESTIGATIONAL NEW DRUGS
- Efficacy of Everolimus in Patients with Advanced Renal Cell Carcinoma Refractory or Intolerant to VEGFR-TKIs and Safety Compared with Prior VEGFR-TKI Treatment
- (2014) Renpei Kato et al. JAPANESE JOURNAL OF CLINICAL ONCOLOGY
- Temsirolimus enhances the efficacy of cetuximab in colon cancer through a CIP2A-dependent mechanism
- (2014) Hsei-Wei Wang et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- Phase I Dose-Escalation Study of 5-Day Intermittent Oral Lapatinib Therapy in Patients With Human Epidermal Growth Factor Receptor 2–Overexpressing Breast Cancer
- (2014) A. Jo Chien et al. JOURNAL OF CLINICAL ONCOLOGY
- Second Malignant Neoplasms in Patients With Cowden Syndrome With Underlying Germline PTEN Mutations
- (2014) Joanne Ngeow et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase 1 trial of the oral AKT inhibitor MK-2206 plus carboplatin/paclitaxel, docetaxel, or erlotinib in patients with advanced solid tumors
- (2014) L Molife et al. Journal of Hematology & Oncology
- Phase I Safety and Pharmacokinetic Study of the PI3K/mTOR Inhibitor SAR245409 (XL765) in Combination with Erlotinib in Patients with Advanced Solid Tumors
- (2014) Pasi A. Jänne et al. Journal of Thoracic Oncology
- PTEN Is a Potent Suppressor of Small Cell Lung Cancer
- (2014) Min Cui et al. MOLECULAR CANCER RESEARCH
- PI3K and cancer: lessons, challenges and opportunities
- (2014) David A. Fruman et al. NATURE REVIEWS DRUG DISCOVERY
- PTEN is a protein tyrosine phosphatase for IRS1
- (2014) Yuji Shi et al. NATURE STRUCTURAL & MOLECULAR BIOLOGY
- Phase I/II study of erlotinib and temsirolimus for patients with recurrent malignant gliomas: North American Brain Tumor Consortium trial 04-02
- (2014) P. Y. Wen et al. NEURO-ONCOLOGY
- A Phase I Study of Temsirolimus and Bryostatin-1 in Patients With Metastatic Renal Cell Carcinoma and Soft Tissue Sarcoma
- (2014) E. R. Plimack et al. ONCOLOGIST
- Molecular Subtypes of Glioblastoma Are Relevant to Lower Grade Glioma
- (2014) Xiaowei Guan et al. PLoS One
- Combined PTEN Mutation and Protein Expression Associate with Overall and Disease-Free Survival of Glioblastoma Patients
- (2014) Jie Xu et al. Translational Oncology
- PTEN function: the long and the short of it
- (2014) Benjamin D. Hopkins et al. TRENDS IN BIOCHEMICAL SCIENCES
- Temsirolimus combined with sorafenib in hepatocellular carcinoma: a phase I dose-finding trial with pharmacokinetic and biomarker correlates
- (2013) R. K. Kelley et al. ANNALS OF ONCOLOGY
- A phase I trial of the IGF-1R antibody Cixutumumab in combination with temsirolimus in patients with metastatic breast cancer
- (2013) Cynthia X. Ma et al. BREAST CANCER RESEARCH AND TREATMENT
- A multicenter phase 1 study of PX-866 in combination with docetaxel in patients with advanced solid tumours
- (2013) D W Bowles et al. BRITISH JOURNAL OF CANCER
- A phase-1b study of everolimus plus paclitaxel in patients with small-cell lung cancer
- (2013) J M Sun et al. BRITISH JOURNAL OF CANCER
- Targeting EGFR and PI3K pathways in ovarian cancer
- (2013) S Glaysher et al. BRITISH JOURNAL OF CANCER
- Ridaforolimus as a single agent in advanced endometrial cancer: results of a single-arm, phase 2 trial
- (2013) N Colombo et al. BRITISH JOURNAL OF CANCER
- A phase II study evaluating the toxicity and efficacy of single-agent temsirolimus in chemotherapy-naïve castration-resistant prostate cancer
- (2013) K Kruczek et al. BRITISH JOURNAL OF CANCER
- Everolimus as second- or third-line treatment of advanced endometrial cancer: ENDORAD, a phase II trial of GINECO
- (2013) I Ray-Coquard et al. BRITISH JOURNAL OF CANCER
- Phase 1 and pharmacodynamic trial of everolimus in combination with cetuximab in patients with advanced cancer
- (2013) Christine A. Ciunci et al. CANCER
- Molecular determinants of outcome with mammalian target of rapamycin inhibition in endometrial cancer
- (2013) Helen J. Mackay et al. CANCER
- Alterations of EGFR, p53 and PTEN that mimic changes found in basal-like breast cancer promote transformation of human mammary epithelial cells
- (2013) Maira M. Pires et al. CANCER BIOLOGY & THERAPY
- Phase I study evaluating the combination of lapatinib (a Her2/Neu and EGFR inhibitor) and everolimus (an mTOR inhibitor) in patients with advanced cancers: South West Oncology Group (SWOG) Study S0528
- (2013) Shirish M. Gadgeel et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- A phase 1b clinical trial of the multi-targeted tyrosine kinase inhibitor lenvatinib (E7080) in combination with everolimus for treatment of metastatic renal cell carcinoma (RCC)
- (2013) Ana M. Molina et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Phase II Study of Everolimus in Patients with Metastatic Colorectal Adenocarcinoma Previously Treated with Bevacizumab-, Fluoropyrimidine-, Oxaliplatin-, and Irinotecan-Based Regimens
- (2013) K. Ng et al. CLINICAL CANCER RESEARCH
- Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of SAR245408 (XL147), an Oral Pan-Class I PI3K Inhibitor, in Patients with Advanced Solid Tumors
- (2013) G. I. Shapiro et al. CLINICAL CANCER RESEARCH
- A Phase I Study of Temsirolimus and Thoracic Radiation in Non–Small-Cell Lung Cancer
- (2013) Saiama N. Waqar et al. Clinical Lung Cancer
- Phase Ib study of tivozanib (AV-951) in combination with temsirolimus in patients with renal cell carcinoma
- (2013) M.N. Fishman et al. EUROPEAN JOURNAL OF CANCER
- Phase 2 Trial of Single-agent Everolimus in Chemotherapy-naive Patients with Castration-resistant Prostate Cancer (SAKK 08/08)
- (2013) Arnoud J. Templeton et al. EUROPEAN UROLOGY
- Concurrent chemoradiotherapy versus induction chemotherapy followed by chemoradiotherapy (sequential approach) in the management of head and neck cancer
- (2013) Jesus C Fabregas et al. Expert Review of Anticancer Therapy
- A mosaic PTEN mutation causing Cowden syndrome identified by deep sequencing
- (2013) Colin C. Pritchard et al. GENETICS IN MEDICINE
- Phase II study of temsirolimus (CCI-779) in women with recurrent, unresectable, locally advanced or metastatic carcinoma of the cervix. A trial of the NCIC Clinical Trials Group (NCIC CTG IND 199)
- (2013) A.V. Tinker et al. GYNECOLOGIC ONCOLOGY
- A dose-finding study of temsirolimus and liposomal doxorubicin for patients with recurrent and refractory bone and soft tissue sarcoma
- (2013) K.A. Thornton et al. INTERNATIONAL JOURNAL OF CANCER
- RTOG 0913: A Phase 1 Study of Daily Everolimus (RAD001) in Combination With Radiation Therapy and Temozolomide in Patients With Newly Diagnosed Glioblastoma
- (2013) Prakash Chinnaiyan et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- Phase I clinical trial of lenalidomide in combination with temsirolimus in patients with advanced cancer
- (2013) Prasanth Ganesan et al. INVESTIGATIONAL NEW DRUGS
- Phase I study of UCN-01 and perifosine in patients with relapsed and refractory acute leukemias and high-risk myelodysplastic syndrome
- (2013) Ivana Gojo et al. INVESTIGATIONAL NEW DRUGS
- Targeted Next-Generation Sequencing Panel (ThyroSeq) for Detection of Mutations in Thyroid Cancer
- (2013) Marina N. Nikiforova et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Toward a NOTCH1/FBXW7/RAS/PTEN–Based Oncogenetic Risk Classification of Adult T-Cell Acute Lymphoblastic Leukemia: A Group for Research in Adult Acute Lymphoblastic Leukemia Study
- (2013) Amélie Trinquand et al. JOURNAL OF CLINICAL ONCOLOGY
- Results of an International Randomized Phase III Trial of the Mammalian Target of Rapamycin Inhibitor Ridaforolimus Versus Placebo to Control Metastatic Sarcomas in Patients After Benefit From Prior Chemotherapy
- (2013) George D. Demetri et al. JOURNAL OF CLINICAL ONCOLOGY
- Everolimus for Previously Treated Advanced Gastric Cancer: Results of the Randomized, Double-Blind, Phase III GRANITE-1 Study
- (2013) Atsushi Ohtsu et al. JOURNAL OF CLINICAL ONCOLOGY
- Randomized Phase III Trial of Temsirolimus Versus Sorafenib As Second-Line Therapy After Sunitinib in Patients With Metastatic Renal Cell Carcinoma
- (2013) Thomas E. Hutson et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase I Study of Neratinib in Combination With Temsirolimus in Patients With Human Epidermal Growth Factor Receptor 2–Dependent and Other Solid Tumors
- (2013) Leena Gandhi et al. JOURNAL OF CLINICAL ONCOLOGY
- A phase I study of ridaforolimus in adult Chinese patients with advanced solid tumors
- (2013) Lian Liu et al. Journal of Hematology & Oncology
- Cixutumumab and temsirolimus for patients with bone and soft-tissue sarcoma: a multicentre, open-label, phase 2 trial
- (2013) Gary K Schwartz et al. LANCET ONCOLOGY
- Perifosine treatment in chronic lymphocytic leukemia: results of a phase II clinical trial andin vitrostudies
- (2013) Daphne R. Friedman et al. LEUKEMIA & LYMPHOMA
- Phase I clinical, pharmacokinetic, and pharmacodynamic study of the Akt-inhibitor triciribine phosphate monohydrate in patients with advanced hematologic malignancies
- (2013) Deepa Sampath et al. LEUKEMIA RESEARCH
- Ovarian and endometrial endometrioid carcinomas have distinct CTNNB1 and PTEN mutation profiles
- (2013) Melissa K McConechy et al. MODERN PATHOLOGY
- MicroRNA-32 (miR-32) regulates phosphatase and tensin homologue (PTEN) expression and promotes growth, migration, and invasion in colorectal carcinoma cells
- (2013) Weiyun Wu et al. Molecular Cancer
- Multicenter Phase II Study of Tivozanib (AV-951) and Everolimus (RAD001) for Patients With Refractory, Metastatic Colorectal Cancer
- (2013) B. M. Wolpin et al. ONCOLOGIST
- A phase II study of temsirolimus and erlotinib in patients with recurrent and/or metastatic, platinum-refractory head and neck squamous cell carcinoma
- (2013) Julie E. Bauman et al. ORAL ONCOLOGY
- Overall Survival Benefits for Combining Targeted Therapy as Second-Line Treatment for Advanced Non-Small-Cell-Lung Cancer: A Meta-Analysis of Published Data
- (2013) Wei-Xiang Qi et al. PLoS One
- Analysis of PTEN Methylation Patterns in Soft Tissue Sarcomas by MassARRAY Spectrometry
- (2013) Liang Yin et al. PLoS One
- Four MicroRNAs Promote Prostate Cell Proliferation with Regulation of PTEN and Its Downstream Signals In Vitro
- (2013) Ling Tian et al. PLoS One
- High-dose accelerated hypofractionated three-dimensional conformal radiotherapy (at 3 Gy/fraction) with concurrent vinorelbine and carboplatin chemotherapy in locally advanced non-small-cell lung cancer: a feasibility study
- (2013) Yue-E Liu et al. Radiation Oncology
- Phase I trial of the combination of the Akt inhibitor nelfinavir and chemoradiation for locally advanced rectal cancer
- (2013) Jeroen Buijsen et al. RADIOTHERAPY AND ONCOLOGY
- MicroRNA-128 promotes proliferation in osteosarcoma cells by downregulating PTEN
- (2013) Lei Shen et al. TUMOR BIOLOGY
- Phase I study of everolimus and mitomycin C for patients with metastatic esophagogastric adenocarcinoma
- (2013) Dominique Werner et al. Cancer Medicine
- Genomic Deletion of PTEN Is Associated with Tumor Progression and Early PSA Recurrence in ERG Fusion-Positive and Fusion-Negative Prostate Cancer
- (2012) Antje Krohn et al. AMERICAN JOURNAL OF PATHOLOGY
- Phase I safety, pharmacokinetic, and pharmacodynamic study of the oral phosphatidylinositol-3-kinase and mTOR inhibitor BGT226 in patients with advanced solid tumors
- (2012) B. Markman et al. ANNALS OF ONCOLOGY
- MiR-124 suppresses cell proliferation in hepatocellular carcinoma by targeting PIK3CA
- (2012) Qingbo Lang et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- A reinvestigation of somatic hypermethylation at the PTEN CpG island in cancer cell lines
- (2012) Luke B Hesson et al. BIOLOGICAL PROCEDURES ONLINE
- Alternative dosing of dual PI3K and MEK inhibition in cancer therapy
- (2012) Elina Jokinen et al. BMC CANCER
- Phase II trial of temsirolimus in patients with metastatic breast cancer
- (2012) Gini F. Fleming et al. BREAST CANCER RESEARCH AND TREATMENT
- Safety, tolerability, pharmacokinetics and pharmacodynamics of AZD8055 in advanced solid tumours and lymphoma
- (2012) A Naing et al. BRITISH JOURNAL OF CANCER
- Perifosine plus lenalidomide and dexamethasone in relapsed and relapsed/refractory multiple myeloma: a Phase I Multiple Myeloma Research Consortium study
- (2012) Andrzej J. Jakubowiak et al. BRITISH JOURNAL OF HAEMATOLOGY
- Two phase 2 trials of the novel Akt inhibitor perifosine in patients with advanced renal cell carcinoma after progression on vascular endothelial growth factor-targeted therapy
- (2012) Daniel C. Cho et al. CANCER
- A Multicenter Phase I Trial of PX-866, an Oral Irreversible Phosphatidylinositol 3-Kinase Inhibitor, in Patients with Advanced Solid Tumors
- (2012) D. S. Hong et al. CLINICAL CANCER RESEARCH
- The Clinical Effect of the Dual-Targeting Strategy Involving PI3K/AKT/mTOR and RAS/MEK/ERK Pathways in Patients with Advanced Cancer
- (2012) T. Shimizu et al. CLINICAL CANCER RESEARCH
- Phase I pharmacokinetic and pharmacodynamic study of the pan-PI3K/mTORC vascular targeted pro-drug SF1126 in patients with advanced solid tumours and B-cell malignancies
- (2012) D. Mahadevan et al. EUROPEAN JOURNAL OF CANCER
- The RAS/RAF/MEK/ERK and the PI3K/AKT signalling pathways: role in cancer pathogenesis and implications for therapeutic approaches
- (2012) Antonella De Luca et al. EXPERT OPINION ON THERAPEUTIC TARGETS
- Complexity in the signaling network: insights from the use of targeted inhibitors in cancer therapy
- (2012) J. S. Logue et al. GENES & DEVELOPMENT
- Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer
- (2012) Siqing Fu et al. GYNECOLOGIC ONCOLOGY
- Phase II trial of combination bevacizumab and temsirolimus in the treatment of recurrent or persistent endometrial carcinoma: A Gynecologic Oncology Group study
- (2012) Edwin A. Alvarez et al. GYNECOLOGIC ONCOLOGY
- Cutaneous T cell lymphoma: update on treatment
- (2012) Uwe Wollina INTERNATIONAL JOURNAL OF DERMATOLOGY
- Randomized Phase III Placebo-Controlled Trial of Letrozole Plus Oral Temsirolimus As First-Line Endocrine Therapy in Postmenopausal Women With Locally Advanced or Metastatic Breast Cancer
- (2012) Antonio C. Wolff et al. JOURNAL OF CLINICAL ONCOLOGY
- Combinatorial drug therapy for cancer in the post-genomic era
- (2012) Bissan Al-Lazikani et al. NATURE BIOTECHNOLOGY
- Phase I Trial of Cixutumumab Combined with Temsirolimus in Patients with Advanced Cancer
- (2011) Aung Naing et al. CLINICAL CANCER RESEARCH
- Phase II trial of temsirolimus in children with high-grade glioma, neuroblastoma and rhabdomyosarcoma
- (2011) Birgit Geoerger et al. EUROPEAN JOURNAL OF CANCER
- Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer—Shifting the paradigm
- (2011) Robert J. Kurman et al. HUMAN PATHOLOGY
- Phase I study of temsirolimus in combination with EKB-569 in patients with advanced solid tumors
- (2011) Alan H. Bryce et al. INVESTIGATIONAL NEW DRUGS
- Phase I and pharmacokinetic study of capecitabine and the oral mTOR inhibitor everolimus in patients with advanced solid malignancies
- (2011) Maarten J. Deenen et al. INVESTIGATIONAL NEW DRUGS
- Perifosine Plus Bortezomib and Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma Previously Treated With Bortezomib: Results of a Multicenter Phase I/II Trial
- (2011) Paul G. Richardson et al. JOURNAL OF CLINICAL ONCOLOGY
- Randomized Placebo-Controlled Phase II Trial of Perifosine Plus Capecitabine As Second- or Third-Line Therapy in Patients With Metastatic Colorectal Cancer
- (2011) Johanna C. Bendell et al. JOURNAL OF CLINICAL ONCOLOGY
- First-in-Man Clinical Trial of the Oral Pan-AKT Inhibitor MK-2206 in Patients With Advanced Solid Tumors
- (2011) Timothy A. Yap et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II Study of the Mammalian Target of Rapamycin Inhibitor Ridaforolimus in Patients With Advanced Bone and Soft Tissue Sarcomas
- (2011) Sant P. Chawla et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase I, Dose-Escalation Study of BKM120, an Oral Pan-Class I PI3K Inhibitor, in Patients With Advanced Solid Tumors
- (2011) Johanna C. Bendell et al. JOURNAL OF CLINICAL ONCOLOGY
- Frequent promoter hypermethylation of BRCA2, CDH13, MSH6, PAX5, PAX6 and WT1 in ductal carcinoma in situ and invasive breast cancer
- (2011) Cathy B Moelans et al. JOURNAL OF PATHOLOGY
- Temsirolimus and bevacizumab, or sunitinib, or interferon alfa and bevacizumab for patients with advanced renal cell carcinoma (TORAVA): a randomised phase 2 trial
- (2011) Sylvie Négrier et al. LANCET ONCOLOGY
- PI3K Pathway Mutations and PTEN Levels in Primary and Metastatic Breast Cancer
- (2011) A. M. Gonzalez-Angulo et al. MOLECULAR CANCER THERAPEUTICS
- The genomic complexity of primary human prostate cancer
- (2011) Michael F. Berger et al. NATURE
- Frequency of Germline PTEN Mutations in Differentiated Thyroid Cancer
- (2011) Rebecca Nagy et al. THYROID
- Phase I trial of oral mTOR inhibitor everolimus in combination with trastuzumab and vinorelbine in pre-treated patients with HER2-overexpressing metastatic breast cancer
- (2010) Guy Jerusalem et al. BREAST CANCER RESEARCH AND TREATMENT
- Role of PTEN promoter methylation in tamoxifen-resistant breast cancer cells
- (2010) Nguyen Thi Thuy Phuong et al. BREAST CANCER RESEARCH AND TREATMENT
- Phase 3 trial of everolimus for metastatic renal cell carcinoma
- (2010) Robert J. Motzer et al. CANCER
- Activating E17K mutation in the gene encoding the protein kinase AKT in a subset of squamous cell carcinoma of the lung
- (2010) Donatella Malanga et al. CELL CYCLE
- A Pharmacodynamic Study of Rapamycin in Men with Intermediate- to High-Risk Localized Prostate Cancer
- (2010) A. J. Armstrong et al. CLINICAL CANCER RESEARCH
- Combination mTOR and IGF-1R Inhibition: Phase I Trial of Everolimus and Figitumumab in Patients with Advanced Sarcomas and Other Solid Tumors
- (2010) R. Quek et al. CLINICAL CANCER RESEARCH
- Akt inhibitors in clinical development for the treatment of cancer
- (2010) Sumanta Kumar Pal et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Involvement of miR-21 in resistance to daunorubicin by regulating PTEN expression in the leukaemia K562 cell line
- (2010) Haitao Bai et al. FEBS LETTERS
- Phase I pharmacokinetic and pharmacodynamic study of triciribine phosphate monohydrate, a small-molecule inhibitor of AKT phosphorylation, in adult subjects with solid tumors containing activated AKT
- (2010) Christopher R. Garrett et al. INVESTIGATIONAL NEW DRUGS
- PTEN mutation spectrum in breast cancers and breast hyperplasia
- (2010) JuLun Yang et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- The PI3K Pathway As Drug Target in Human Cancer
- (2010) Kevin D. Courtney et al. JOURNAL OF CLINICAL ONCOLOGY
- New insights in sarcoma oncogenesis: a comprehensive analysis of a large series of 160 soft tissue sarcomas with complex genomics
- (2010) Laure Gibault et al. JOURNAL OF PATHOLOGY
- Phase II Trial of Gefitinib and Everolimus in Advanced Non-small Cell Lung Cancer
- (2010) Katharine A. Price et al. Journal of Thoracic Oncology
- Inhibitors of phosphatidylinositol-3-kinase in cancer therapy
- (2010) Nathan T. Ihle et al. MOLECULAR ASPECTS OF MEDICINE
- FDA Approval Summary: Temsirolimus as Treatment for Advanced Renal Cell Carcinoma
- (2010) V. E. Kwitkowski et al. ONCOLOGIST
- High frequency of PTEN, PI3K, and AKT abnormalities in T-cell acute lymphoblastic leukemia
- (2009) A. Gutierrez et al. BLOOD
- Putative chemopreventive molecules can increase Nrf2-regulated cell defense in some human cancer cell lines, resulting in resistance to common cytotoxic therapies
- (2009) Liangao Hu et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- AZD8055 Is a Potent, Selective, and Orally Bioavailable ATP-Competitive Mammalian Target of Rapamycin Kinase Inhibitor with In vitro and In vivo Antitumor Activity
- (2009) C. M. Chresta et al. CANCER RESEARCH
- Targeting the PI3K signaling pathway in cancer
- (2009) Kwok-Kin Wong et al. CURRENT OPINION IN GENETICS & DEVELOPMENT
- Phase II Randomized Study of Neoadjuvant Everolimus Plus Letrozole Compared With Placebo Plus Letrozole in Patients With Estrogen Receptor–Positive Breast Cancer
- (2009) José Baselga et al. JOURNAL OF CLINICAL ONCOLOGY
- Discovery of molecular subtypes in leiomyosarcoma through integrative molecular profiling
- (2009) A H Beck et al. ONCOGENE
- Mutational analysis of oncogenic AKT E17K mutation in common solid cancers and acute leukaemias
- (2008) M S Kim et al. BRITISH JOURNAL OF CANCER
- An Integrative Genomic and Proteomic Analysis of PIK3CA, PTEN, and AKT Mutations in Breast Cancer
- (2008) K. Stemke-Hale et al. CANCER RESEARCH
- PIK3CA Mutations and Copy Number Gains in Human Lung Cancers
- (2008) H. Yamamoto et al. CANCER RESEARCH
- AKT1 E17K in human solid tumours
- (2008) F E Bleeker et al. ONCOGENE
- Phosphatidylinositol 3-Kinase/Akt and Ras/Raf-Mitogen-Activated Protein Kinase Pathway Mutations in Anaplastic Thyroid Cancer
- (2007) Libero Santarpia et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now